“Reta peptide” is an informal term used to refer to retatrutide, an investigational peptide also known by its development code LY3437943.

Retatrutide is not a combination of three separate peptides. It is a single engineered peptide designed to activate three different hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). This is why researchers describe retatrutide as a triple receptor agonist.  

But describing retatrutide simply as a “peptide” leaves out much of what makes the molecule scientifically distinctive. Its amino-acid sequence was deliberately engineered, it contains specific non-coded amino acids, and a fatty-acid component is attached to the molecule to influence its pharmacokinetic properties.

So what exactly is reta peptide, how is it constructed, and how can one peptide interact with three different receptors?

Is Retatrutide a Peptide?

Yes. Retatrutide is a peptide.

Peptides are molecules made from amino acids joined together by peptide bonds. Retatrutide consists of a 39-amino-acid peptide backbone engineered from a GIP peptide backbone.

Its structure is not simply identical to naturally occurring GIP.

Researchers developing LY3437943 introduced modifications at particular positions in the peptide. The original development research describes three non-coded amino-acid residues at positions 2, 13 and 20.

At position 2, α-aminoisobutyric acid (Aib) improves resistance to cleavage by the enzyme DPP-4. A second Aib at position 20 contributes to GIP activity and pharmacokinetic properties. A modified leucine at position 13 contributes to glucagon and GIP receptor activity.  

Retatrutide is therefore better understood as an engineered peptide molecule rather than simply a synthetic copy of one naturally occurring hormone.

What Is Retatrutide Peptide Made Of?

The basic molecular design has two important components:

1. A 39-amino-acid engineered peptide backbone.
2. A C20 fatty diacid attached through a linker at the lysine residue at position 17.

The fatty-acid component has an important purpose. It promotes binding to albumin, a protein found in the blood. The developers used this as a strategy to extend the molecule’s pharmacokinetic half-life.  

So when people refer to “reta peptide”, they are referring to a specifically engineered molecular structure rather than an unspecified class of peptide.

The design also helps explain something that can initially sound counterintuitive: one peptide can activate three different receptors.

Why Is Retatrutide Called a Triple Agonist?

An agonist is a molecule that binds to and activates a receptor.

Retatrutide has been engineered to activate:

That is what the word “triple” refers to.

It does not mean that retatrutide contains three separate drugs or three separate peptides.

The original pharmacological research found that LY3437943 had agonist activity at all three human receptors. Researchers subsequently went further and examined how the molecule interacts with each receptor.

A 2024 structural study examined retatrutide using cryo-electron microscopy. Researchers determined its structure when bound separately to GLP-1R, GIPR and GCGR.  

The researchers identified interactions shared across all three receptors. They also found structural differences in how each receptor accommodates the peptide. Together, these findings help explain how the same molecule can produce agonist activity across all three receptor systems.  

In other words, triple agonism is a property of one engineered peptide, not a mixture of three peptides.

How Can One Peptide Activate Three Different Receptors?

GIP, GLP-1 and glucagon are different hormones, but their receptors belong to the same broader family of receptors.

Retatrutide was designed so that its peptide structure can form the interactions required to engage all three.

Structural research found that retatrutide forms a continuous helical structure when interacting with these receptors. Its N-terminal region penetrates the receptor’s transmembrane domain. Another region interacts with extracellular parts of the receptor.  

The researchers found both conserved interactions and receptor-specific contacts. This combination helps explain retatrutide’s ability to activate GLP-1R, GIPR and GCGR.

This provides a structural explanation for how one engineered peptide can interact with three distinct receptor systems.

How Is Retatrutide Different From a GLP-1 Agonist?

The important distinction is the number and combination of receptors activated.

A GLP-1 receptor agonist such as semaglutide activates GLP-1R. Tirzepatide has agonist activity at both GIPR and GLP-1R. Retatrutide adds glucagon receptor agonism to GIP and GLP-1 receptor agonism.  

Conceptually:

Semaglutide: GLP-1R
Tirzepatide: GIPR + GLP-1R
Retatrutide: GIPR + GLP-1R + GCGR

This is why describing retatrutide simply as another “GLP-1 peptide” is incomplete. GLP-1 receptor activation is one component of its pharmacology, but not the entire mechanism.

The three-receptor design is also why retatrutide is described in the scientific literature as a unimolecular triple agonist. 

For a clinical comparison of these different mechanisms, our retatrutide vs Ozempic analysis examines how the two treatments performed in a Phase 3 head-to-head trial.

Is Retatrutide a GLP-3?

No. “GLP-3” is not a scientific classification for retatrutide.

The term has been used informally to describe triple hormone receptor agonists. However, retatrutide does not activate a receptor called “GLP-3”.

Its three receptor targets are GIPR, GLP-1R and GCGR.

What Does Activating Three Receptors Actually Mean?

GIP, GLP-1 and glucagon receptors participate in different but overlapping metabolic signalling pathways. Retatrutide’s ability to activate all three is the central pharmacological idea behind its design.

However, receptor count alone does not determine clinical effects. The relative activity at each receptor, dose and interaction between these signalling pathways all matter.

Our separate analysis of what retatrutide does examines the mechanism and clinical evidence in more detail.

Is Reta Peptide the Same as Retatrutide Sold Online?

This distinction is important.

Scientifically, “reta peptide” refers to retatrutide. But a product being labelled “reta”, “retatrutide” or “research peptide” does not establish that it contains authentic retatrutide.

Our analysis of whether retatrutide is available in Australia explains the current TGA status and why products labelled as retatrutide can still be found online.

This is particularly relevant in Australia because retatrutide remains an unapproved therapeutic good. The Therapeutic Goods Administration states that unapproved peptide products have not been assessed for safety, quality or effectiveness. It also warns that product labelling may be inaccurate or misleading.  

There is now direct Australian evidence demonstrating this problem.

In September 2026, the TGA reported laboratory testing of a product sold as retatrutide following a serious adverse-event report. The tested product contained no retatrutide. Instead, the TGA detected undeclared semaglutide at approximately eight times the level found in semaglutide products assessed by the TGA and included in the Australian Register of Therapeutic Goods.  

This finding relates to the specific product tested. It does not establish the contents of every product sold online as retatrutide. It does, however, demonstrate why a product label alone cannot establish that a substance is equivalent to the retatrutide characterised in published research.

What Do We Know About Retatrutide From Clinical Research?

Retatrutide has progressed from early pharmacological and Phase 1 research into larger Phase 2 and Phase 3 clinical programmes.

Those studies answer different questions from the molecular research discussed above.

Clinical trials investigate outcomes in people, including efficacy, tolerability and adverse events. Structural and pharmacological studies help explain what the molecule is and how it interacts with its receptor targets.

The clinical programme has also produced a growing body of safety evidence. Our analysis of retatrutide side effects examines the adverse events observed across clinical trials. Our article examining whether retatrutide is safe looks more broadly at what the current evidence can and cannot establish.

Identifying the molecule, understanding its pharmacology and evaluating its clinical safety are related questions, but they are not the same question.

So, What Is Reta Peptide?

“Reta peptide” is an informal term for retatrutide.

Retatrutide is a 39-amino-acid engineered peptide developed from a GIP peptide backbone. Its structure incorporates specific amino-acid modifications and a fatty-acid component designed to influence its stability and pharmacokinetic properties.

Most importantly, it is one molecule capable of activating three receptor systems: GIPR, GLP-1R and GCGR.

That is why retatrutide is scientifically described as a triple receptor agonist.

It is also important to distinguish the molecule studied in controlled research from products sold online as “reta peptide”. A label alone does not establish molecular identity, purity or equivalence to clinical-trial retatrutide.

Retatrutide Australia follows the evolving scientific and regulatory evidence surrounding retatrutide from an Australian research perspective.

Frequently Asked Questions

What does “reta” stand for?

“Reta” is shorthand for retatrutide. It is not the name of a separate peptide or receptor.

Is retatrutide a GLP-1 peptide?

Retatrutide has GLP-1 receptor agonist activity, but describing it only as a GLP-1 peptide is incomplete. It also activates GIP and glucagon receptors. This three-receptor activity is why researchers describe it as a triple agonist.

Is retatrutide GLP-3?

No. GLP-3 is not a scientific classification for retatrutide. Retatrutide is a single peptide with agonist activity at GIPR, GLP-1R and GCGR.

Is retatrutide approved in Australia?

No. As of September 2026, retatrutide has not been approved by the TGA. It remains investigational and is still undergoing clinical development. The TGA specifically identifies retatrutide among unapproved peptide products and states that these products have not been evaluated by the TGA for safety, quality or effectiveness.

Research Sources

Coskun T, et al. LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept. Cell Metabolism, 2022.

Li W, et al. Structural Insights Into the Triple Agonism at GLP-1R, GIPR and GCGR Manifested by Retatrutide. Cell Discovery, 2024.

Therapeutic Goods Administration. Understanding Your Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products, April 2026.

Therapeutic Goods Administration. TGA Tests Counterfeit Retatrutide Product Following Serious Adverse Event Report, September 2026.